title: Inhibition of Erythroleukemia Cell Growth by Triplex-forming RNAs.
abstract: OBJECTIVE
  We have previously reported that oligodeoxyribonucleotides, designed to bind in a triplex fashion to a specific p53 binding site homology, inhibit the proliferation of colon cancer cells in vitro and in vivo. The present study was designed to extend these observations and to determine whether ribonucleic acid (RNA) generated from a retroviral vector (RVV) and possessing a corresponding triplex forming site can, in a similar fashion, inhibit proliferation of p53-null K-562 leukemia cells. Viral vectors may offer advantages over oligonucleotides for tumor treatment. RVVs have the potential to be taken up more efficiently than oligonucleotides and to be expressed continuously and long-term, circumventing the need for repeated and frequent oligomer administration.
  
  
  METHODS
  The p53-null human erythroleukemia cell line, K-562, was stably transfected with a tetracycline-repressible p53 expression construct (p53/pUHD10-3). p53 protein in these cells is expressed in the absence of tetracycline but down-regulated upon tetracycline treatment. Triplex-forming oligonucleotides [Hoog 1 (experimental) and Hoog 3 (control)] were cloned into RVVs in order to generate triplex-forming fusion mRNAs. Naive K-562 cells and p53/pUHD10-3-transfected K-562 cells (with and without tetracycline treatment) were infected with viruses that express the triplex-forming RNAs. Cell growth was measured by BrdU incorporation into DNA.
  
  
  RESULTS
  RVVs encoding Hoog 1, in both orientations, inhibit the growth of naive K-562 cells and p53-transfected, tet-repressed K-562 cells. p53 expression in K-562 cells decreases growth to the same extent as Hoog 1 RVV treatment. However, Hoog 1-RVV does not further inhibit growth of p53-expressing K-562 cells. Treatment with an RVV encoding the control, Hoog 3, has no growth inhibitory effect.
  
  
  CONCLUSIONS
  Triple helix-forming RNAs directed to a p53 consensus sequence homology reduce leukemia cell proliferation, suggesting a novel method of treatment.
authors: Department of Research, Ochsner Clinic Foundation, New Orleans, LA.
authors: Richard N
authors: RN
authors: Re
authors: Zhuo
authors: Z
authors: Zhang
authors: Julia L
authors: JL
authors: Cook
references: Proc Soc Exp Biol Med. 1981 Apr;166(4):546-50
references: 7194480
references: Nat Med. 2002 Mar;8(3):282-8
references: 11875500
references: Cell. 1992 Aug 21;70(4):523-6
references: 1505019
references: Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5547-51
references: 1319065
references: Biotechniques. 1989 Oct;7(9):980-2, 984-6, 989-90
references: 2631796
references: Cancer Lett. 2004 Jun 8;209(1):51-3
references: 15145520
references: Biochem Biophys Res Commun. 1989 Aug 30;163(1):649-56
references: 2775292
references: Int J Cancer. 1979 Feb;23(2):143-7
references: 367973
references: Nucleic Acids Res. 1992 Apr 11;20(7):1777-84
references: 1579471
references: Cancer Res. 1993 Oct 15;53(20):4772-5
references: 8402659
references: J Exp Med. 1988 Mar 1;167(3):873-86
references: 3280726
references: Oncogene. 1995 Aug 17;11(4):723-33
references: 7651736
references: Am J Med Sci. 1996 Feb;311(2):65-72
references: 8615376
references: Blood. 1975 Mar;45(3):321-34
references: 163658
references: Proc Natl Acad Sci U S A. 1997 May 27;94(11):5854-9
references: 9159164
references: Nat Genet. 1992 Apr;1(1):45-9
references: 1301998
references: Cancer Gene Ther. 1997 Mar-Apr;4(2):105-12
references: 9080119